Browse CD33

Summary
SymbolCD33
NameCD33 molecule
Aliases SIGLEC3; SIGLEC-3; FLJ00391; sialic acid binding Ig-like lectin 3; CD33 antigen (gp67); gp67; sialic acid-bi ......
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Single-pass type I membrane protein.
Domain PF00047 Immunoglobulin domain
PF07686 Immunoglobulin V-set domain
Function

Putative adhesion molecule of myelomonocytic-derived cells that mediates sialic-acid dependent binding to cells. Preferentially binds to alpha-2,6-linked sialic acid. The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. In the immune response, may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. Induces apoptosis in acute myeloid leukemia (in vitro).

> Gene Ontology
 
Biological Process -
Molecular Function GO:0030246 carbohydrate binding
Cellular Component GO:0009897 external side of plasma membrane
GO:0098552 side of membrane
> KEGG and Reactome Pathway
 
KEGG hsa04640 Hematopoietic cell lineage
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-168256: Immune System
R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
R-HSA-168249: Innate Immune System
R-HSA-6798695: Neutrophil degranulation
Summary
SymbolCD33
NameCD33 molecule
Aliases SIGLEC3; SIGLEC-3; FLJ00391; sialic acid binding Ig-like lectin 3; CD33 antigen (gp67); gp67; sialic acid-bi ......
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CD33 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CD33 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
24504024Acute Myeloid LeukemiaPromote immunity (T cell function); essential for immunotherapyChimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. AML cells frequently overexpress the myeloid antigens CD33 and CD123, for which specific CARs can be generated.
18326813Acute Myeloid LeukemiaInhibit immunity (T cell function); immunotherapy targetSimultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts. Targeting CD33 or CD45 is currently exploited for immunotherapy of acute myeloid leukemia (AML).
23690482Acute Myeloid LeukemiaInhibit immunity (NK cell function); immunotherapy targetWe determined whether a novel bispecific killer cell engager (BiKE) signaling through CD16 and targeting CD33 could activate NK cells at high potency against acute myelogenous leukemia (AML) targets. Combination treatment with CD16 × 33 BiKE and ADAM17 inhibitor resulted in inhibition of CD16 shedding in NK cells, and enhanced NK cell activation.
24300852Acute Myeloid LeukemiaInhibit immunity; Candidate for immunotherapy targetIn MS-5 feeder cell-based long-term cultures that supported the growth of primary AML blasts for up to 36 days, AMG 330 efficiently recruited and expanded residual CD3(+)/CD45RA(-)/CCR7(+) memory T cells within the patient sample. Targeting CD33 ex vivo using AMG 330 in primary AML samples led to T cell recruitment and expansion and remarkable antibody-mediated cytotoxicity, suggesting efficient therapeutic potential in vivo.
24216507Myelodysplastic SyndromeInhibit immunityUsing multiple transfected cell models, we found that MDSC expansion is driven by the interaction of the proinflammatory molecule S100A9 with CD33. These findings indicate that primary bone marrow expansion of MDSC driven by the S100A9/CD33 pathway perturbs hematopoiesis and contributes to the development of MDS.
29856956Acute Myeloid LeukemiaResistant to immunotherapyGenetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. For example, targeting the canonical myeloid marker CD33 in acute myeloid leukemia (AML) results in toxicity from destruction of normal myeloid cells. CD33-deficient cells were impervious to CD33-targeting CAR T cells, allowing for efficient elimination of leukemia without myelotoxicity.
25174587leukemiaInhibit immunityThe data from some clinical trials on the efficacy of GO support the conclusion that CD33 is a valid target for some subtypes of AML, mainly in favorable and intermediate risk groups
Summary
SymbolCD33
NameCD33 molecule
Aliases SIGLEC3; SIGLEC-3; FLJ00391; sialic acid binding Ig-like lectin 3; CD33 antigen (gp67); gp67; sialic acid-bi ......
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CD33 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCD33
NameCD33 molecule
Aliases SIGLEC3; SIGLEC-3; FLJ00391; sialic acid binding Ig-like lectin 3; CD33 antigen (gp67); gp67; sialic acid-bi ......
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CD33 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2340.495
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3580.728
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.140.852
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1660.617
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0970.932
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4970.717
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1190.788
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3030.748
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.6320.554
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3530.771
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.5220.772
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2190.191
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CD33 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.45.51.90.66
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.45.12.30.647
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 382710.57.43.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161418.814.34.51
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCD33
NameCD33 molecule
Aliases SIGLEC3; SIGLEC-3; FLJ00391; sialic acid binding Ig-like lectin 3; CD33 antigen (gp67); gp67; sialic acid-bi ......
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD33. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCD33
NameCD33 molecule
Aliases SIGLEC3; SIGLEC-3; FLJ00391; sialic acid binding Ig-like lectin 3; CD33 antigen (gp67); gp67; sialic acid-bi ......
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD33. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD33.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCD33
NameCD33 molecule
Aliases SIGLEC3; SIGLEC-3; FLJ00391; sialic acid binding Ig-like lectin 3; CD33 antigen (gp67); gp67; sialic acid-bi ......
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD33. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCD33
NameCD33 molecule
Aliases SIGLEC3; SIGLEC-3; FLJ00391; sialic acid binding Ig-like lectin 3; CD33 antigen (gp67); gp67; sialic acid-bi ......
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CD33 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCD33
NameCD33 molecule
Aliases SIGLEC3; SIGLEC-3; FLJ00391; sialic acid binding Ig-like lectin 3; CD33 antigen (gp67); gp67; sialic acid-bi ......
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CD33 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCD33
NameCD33 molecule
Aliases SIGLEC3; SIGLEC-3; FLJ00391; sialic acid binding Ig-like lectin 3; CD33 antigen (gp67); gp67; sialic acid-bi ......
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CD33 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CD33.
ID Name Drug Type Targets #Targets
DB00056Gemtuzumab ozogamicinBiotechC1QA, C1QB, C1QC, C1R, C1S, CD33, FCGR1A, FCGR2A, FCGR2B, FCGR2C, ......12